Skip to main content
OpenTrials

Clinical trial condition

Haemophilia A

Explore clinical trials studying Haemophilia A. Study availability and eligibility vary by location and protocol.

76 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Haemophilia A trial results

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

NCT02941354

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Chicago, Illinois, United States
  • Novo Nordisk Investigational Site Peoria, Illinois, United States
  • Novo Nordisk Investigational Site Memphis, Tennessee, United States
  • Novo Nordisk Investigational Site Richmond, Virginia, United States
View all 15 locations
View Trial Details
Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

NCT02246894

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +7 more
Locations
  • Children's Haematology and Oncology Clinic, Ul. W. Chodzki Str., Lublin Voivodeship, Poland
  • Academic Children's Hospital, Children's Haematology and Oncology, Clinic 265 Wielicka str. Krakow, Poland
  • Specialist Centre for Medical Care of Mother and Children, Internal Ward 1, 7/8 Dr B. Krysiewicza str. Poznan, Poland
  • Department of Paediatrics, Haematology and Oncology, Medical University of Warsaw, 24 Marszalkowska str. Warsaw, Poland
View Trial Details
Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

NCT02246868

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +7 more
Locations
  • Klinika Haematologii, Akademia Medyczna w Bialymstokiu, ul. Bialystok, Poland
  • Klinika Haematologii, Akademia Medyczna w Gdansku, u. Gdansk, Poland
  • Klinika Haematologii, Akademia Medyczna w Lodzi, ul. Lodz, Poland
  • Klinika Haematologii, Akademia Medyczna w Lublinie, ul. Lublin, Poland
View Trial Details
Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

NCT02250482

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +7 more
Locations
  • Klinika Haematologii, Akademia Medyczna w Gdansku, ul. Debinki 7, 80-211 Gdansk, Poland
  • Klinika Haematologii, Akademia Medyczna w Lublinie, ul. Dr K Jaczewskiego 8, 20-090, Lublin, Poland
  • Klinika Haematologii, Akademia Medyczna w Poznaniu, ul. Szkolna 8/12, 61-833 Poznan, Poland
  • Haemophilia Centre, Addenbrooke's Hospital, Hills Road Cambridge, United Kingdom
View Trial Details
Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT02920398

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Torrance, California, United States
  • Novo Nordisk Investigational Site Iowa City, Iowa, United States
  • Novo Nordisk Investigational Site Baltimore, Maryland, United States
  • Novo Nordisk Investigational Site Dayton, Ohio, United States
View all 14 locations
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

NCT00984126

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Tampa, Florida, United States
  • Novo Nordisk Investigational Site Atlanta, Georgia, United States
View all 57 locations
View Trial Details
Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

NCT02490787

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Torrance, California, United States
  • Novo Nordisk Investigational Site Indianapolis, Indiana, United States
  • Novo Nordisk Investigational Site Iowa City, Iowa, United States
  • Novo Nordisk Investigational Site Baltimore, Maryland, United States
View all 34 locations
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

NCT01138501

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Orange, California, United States
  • Novo Nordisk Investigational Site Torrance, California, United States
  • Novo Nordisk Investigational Site Tampa, Florida, United States
View all 38 locations
View Trial Details
Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

NCT00840086

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • Novo Nordisk Investigational Site Little Rock, Arkansas, United States
  • Novo Nordisk Investigational Site Long Beach, California, United States
  • Novo Nordisk Investigational Site Tampa, Florida, United States
  • Novo Nordisk Investigational Site Atlanta, Georgia, United States
View all 63 locations
View Trial Details
Completed

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

NCT00486278

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +11 more
Locations
  • Novo Nordisk Investigational Site Los Angeles, California, United States
  • Novo Nordisk Investigational Site Augusta, Georgia, United States
  • Novo Nordisk Investigational Site Chicago, Illinois, United States
  • Novo Nordisk Investigational Site Indianapolis, Indiana, United States
View all 45 locations
View Trial Details

Related conditions